Celularity Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELU research report →
About the company
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases.
- CEO
- Robert Joseph Hariri
- IPO
- 2019
- Employees
- 120
- HQ
- Florham Park, NJ, US
Price Chart
- Market Cap
- $14.91M
- P/E
- -0.17
- P/S
- 0.56
- P/B
- -0.42
- EV/EBITDA
- -0.64
- Div Yield
- 0.00%
- Gross Margin
- 76.04%
- Op Margin
- -230.92%
- Net Margin
- -345.44%
- ROE
- 411.46%
- ROIC
- -151.11%
- Revenue
- $26.55M · -51.03%
- Net Income
- $-91,800,000 · -58.57%
- EPS
- $-3.59 · -35.75%
- Op Income
- $-61,308,000
- FCF YoY
- -101.98%
- 52W High
- $4.35
- 52W Low
- $0.56
- 50D MA
- $0.85
- 200D MA
- $1.38
- Beta
- 0.54
- Avg Volume
- 136.38K
Get TickerSpark's AI analysis on CELU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Philip & Daniele Barach Family Trust | other | 1,204,819 |
| Jun 19, 26 | Philip & Daniele Barach Family Trust | other | 839,160 |
| Jun 19, 26 | Barach Philip Alan | other | 1,204,819 |
| Jun 19, 26 | Barach Philip Alan | other | 839,160 |
| Jun 19, 26 | Barach Daniele Wolf | other | 1,204,819 |
| Jun 19, 26 | Barach Daniele Wolf | other | 839,160 |
| Dec 19, 25 | Barach Philip Alan | other | 1,204,819 |
| Jun 19, 26 | Barach Philip Alan | other | 839,160 |
| Dec 19, 25 | Barach Daniele Wolf | other | 1,204,819 |
| Jun 19, 26 | Barach Daniele Wolf | other | 839,160 |
Our CELU coverage
Recent articles, reports, and earnings notes.
No research on CELU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELU report →Similar companies
Peers in the same neighborhood.